Phase transition pressure rises; cure trials keep scaling
LISTEN
Direct audio file (MP3)Cure momentum stays visible even as the world’s operating system strains: global active cure-related trials total 21,311, while new Wire signals and cure research signals keep arriving at high volume. Today’s top systems signal is infrastructure stress—MEED reports AI is expanding electricity demand, forcing power grids to confront capacity limits, a classic phase-transition constraint where compute growth outruns planning. On the medical side, Merck and Moderna’s personalized mRNA cancer vaccine intismeran autogene cleared a large randomized blinded Phase 3 trial for melanoma recurrence, cutting recurrence by half, while Japan approved ORZEYFUL for narcolepsy type 1 and the EU authorized trofinetide for neurobehavioral symptoms of Rett syndrome. If the grid can’t keep up, progress risks slowing; if it can, the next wave of AI-enabled biology and platform usability could widen the cure window. The window is still open.
MEED reports AI is expanding electricity demand, stressing grid capacity.
Infrastructure owners and compute builders gain leverage from timing, while humanity’s cure acceleration depends on power systems scaling fast enough to avoid bottlenecks.
Track grid capacity announcements and export/control enforcement closely over the next 24–72 hours as compute growth tests real-world constraints.